COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic

As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did descriptions of an associated coagulopathy and thrombotic complications. Hospitals created institutional protocols for inpatient management of COVID-19 coagulopathy and thrombosis in response to this developing data. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Parks, Anna L., Auerbach, Andrew D., Schnipper, Jeffrey L., Anstey, James E., Sterken, David G., Hecht, Todd E.H., Fang, Margaret C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to the Editors-in-Chief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492800/
https://www.ncbi.nlm.nih.gov/pubmed/32977136
http://dx.doi.org/10.1016/j.thromres.2020.09.018
Descripción
Sumario:As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did descriptions of an associated coagulopathy and thrombotic complications. Hospitals created institutional protocols for inpatient management of COVID-19 coagulopathy and thrombosis in response to this developing data. We collected and analyzed protocols from 21 US academic medical centers developed between January and May 2020. We found greatest consensus on recommendations for heparin-based pharmacologic venous thromboembolism (VTE) prophylaxis in COVID-19 patients without contraindications. Protocols differed regarding incorporation of D-dimer tests, dosing of VTE prophylaxis, indications for post-discharge pharmacologic VTE prophylaxis, how to evaluate for VTE, and the use of empiric therapeutic anticoagulation. These findings support ongoing efforts to establish international, evidence-based guidelines.

Ejemplares similares